Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics ( (ATHE) ) has issued an update.
Alterity Therapeutics announced positive results from their ATH434 Phase 2 trial, presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. The trial demonstrated that ATH434 slows disease progression and stabilizes orthostatic hypotension in patients with Multiple System Atrophy (MSA). New analyses increased confidence in the trial results, showing significant efficacy at a 75 mg dose. The company aims to advance ATH434 development and improve MSA treatment paradigms, reinforcing its potential market leadership position.
The most recent analyst rating on (ATHE) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
Alterity Therapeutics faces significant challenges with profitability and cash flow, which are critical for its long-term success. The technical indicators suggest a bearish trend, and the valuation metrics highlight the company’s unprofitability. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Their primary product, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, particularly targeting Multiple System Atrophy (MSA) and other Parkinsonian disorders.
Average Trading Volume: 78,802
Technical Sentiment Signal: Hold
Current Market Cap: $71.68M
Learn more about ATHE stock on TipRanks’ Stock Analysis page.